Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study.
- DOI
- 10.1186/s13058-025-02108-4
- Published
- 2025 Sep 29
- Container
- Breast cancer research : BCR
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s13058-025-02108-4,
title = {Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study.},
author = {Fanucci K and Yeh ED and Shi R and Qin L and Bay CP and DiLullo M and Patel A and Moore M and Herbert ZT and Harrison BT and Nakhlis F and Bellon J and Warren L and Guerriero JL and Tolaney SM and Regan M and Overmoyer B and Van Laere S and Lynce F},
year = {2025},
journal = {Breast cancer research : BCR},
doi = {10.1186/s13058-025-02108-4},
url = {https://doi.org/10.1186/s13058-025-02108-4}
}RIS
TY - JOUR TI - Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study. AU - Fanucci K AU - Yeh ED AU - Shi R AU - Qin L AU - Bay CP AU - DiLullo M AU - Patel A AU - Moore M AU - Herbert ZT AU - Harrison BT AU - Nakhlis F AU - Bellon J AU - Warren L AU - Guerriero JL AU - Tolaney SM AU - Regan M AU - Overmoyer B AU - Van Laere S AU - Lynce F PY - 2025 JO - Breast cancer research : BCR DO - 10.1186/s13058-025-02108-4 UR - https://doi.org/10.1186/s13058-025-02108-4 ER -
APA
K, F., ED, Y., R, S., L, Q., CP, B., M, D., A, P., M, M., ZT, H., BT, H., F, N., J, B., L, W., JL, G., SM, T., M, R., B, O., S, V. L., & F, L. (2025). Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study.. Breast cancer research : BCR. https://doi.org/10.1186/s13058-025-02108-4
Source records
- pubmed · retrieved 2026-09-26T00:02:09.611Z
- europe-pmc · retrieved 2026-09-26T00:02:09.622Z
- doaj · retrieved 2026-09-26T00:02:09.624Z